Ricevi le ultime notizie sulle azioni Mind Medicine con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di MNMD

Ultime notizie per

Mind Medicine

Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).

Mind Medicine (MindMed) Inc. - Common Shares

Mind Medicine Inc

Press Releases

Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032

MindMed Announces New Employee Inducement Grants

MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025

MindMed Reports Q2 2025 Financial Results and Business Updates

MindMed to Participate in September Investor Conferences

Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)

New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)

ATAI

CMPS

CYBN

MNMD

SAGE

Amphastar Pharmaceuticals, Inc. - Common Stock

Amphastar Pharma

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Arvinas

Collegium Pharmaceutical, Inc. - Common Stock

Collegium Pharmaceutical

Cormedix

Cronos Group

Enliven Therapeutics, Inc. - Common Stock

Enliven Therapeutics

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals

EyePoint Pharmaceuticals, Inc. - Common Stock

EyePoint Pharmaceuticals

GH Research

Innoviva

MBX Biosciences

Nektar Therapeutics

Oculis Holding

Pacira BioSciences

Phathom Pharmaceuticals, Inc. - Common Stock

Phathom Pharmaceuticals

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics

Septerna

SIGA Technologies

SNDL

Theravance Biopharma, Inc. - Ordinary Shares

Theravance Biopharma

Terns Pharmaceuticals, Inc. - Common Stock

Comments

Mind Medicine Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO